Financial Performance (₹ in lakhs)

Key Financial Figures for FY 2025-26:

  • Revenue from Operations: ₹9,205.17 (18.73% increase YoY from ₹7,753.13)
  • Other Income: ₹50.72 (37.38% increase YoY from ₹36.92)
  • Total Expenditure: ₹7,652.41 (13.28% increase YoY from ₹6,755.32)
  • Profit Before Tax: ₹1,603.48 (54.97% increase YoY from ₹1,034.73)
  • Profit After Tax: ₹1,118.12 (55.08% increase YoY from ₹720.99)
  • Basic Earnings Per Share: ₹6.32 (46.30% increase YoY from ₹4.32)

Dividend Information

  • Board recommended a final dividend of ₹2.00 per equity share (20% of face value) for FY 2025-26
  • Record Date: Wednesday, July 08, 2026
  • Dividend payment subject to shareholder approval at AGM
  • Dividend will be paid within 30 days from date of declaration
  • TDS rates: 10% for shareholders with valid PAN, 20% for those without PAN

Capital Structure

  • Paid-up equity share capital: ₹22,69,83,630
  • Number of equity shares: 2,26,98,363 of ₹10 each
  • IPO of 60,00,000 equity shares at ₹70 per share (including premium of ₹60) completed on January 29, 2026
  • Company listed on BSE SME platform effective February 02, 2026

Board of Directors

Composition as of March 31, 2026:

  • Dr. Moses Joseph Arunkumar (Managing Director)
  • Dr. Fenn Kavitha Fenn Arunkumar (Whole-time Director)
  • Dr. Arunkumar Nalina (Non-Executive Director)
  • Mr. Noyel Arunkumar (Non-Executive Director)
  • Mr. C.N. Srinivasan (Independent Director)
  • Mr. Ranganathan Mukundan (Independent Director)
  • Mr. Salaivel Pratheep (Independent Director)
  • Mr. Kumarasamy Sureshkumar (Independent Director)

Key Managerial Personnel:

  • Company Secretary: CS. Yuvaraj Saravanan
  • Chief Financial Officer: Mr. Daniel Dayanand Fenn

Director Re-appointment

  • Dr. Arunkumar Nalina (DIN: 07495044) retires by rotation and offers herself for re-appointment as Non-Executive Director
  • Resolution for re-appointment included in AGM agenda

Annual General Meeting

15th AGM Details:

  • Date: Wednesday, July 15, 2026
  • Time: 12:00 Noon (IST)
  • Mode: Video Conference/Other Audio Visual Means (OAVM)
  • Cut-off date for determining shareholders entitled to vote: July 08, 2026

Agenda Items:

1. Adoption of audited financial statements for FY 2025-26

2. Declaration of final dividend of ₹2 per equity share

3. Re-appointment of Dr. Arunkumar Nalina as Non-Executive Director

Business Review and Outlook

  • Company focuses on Neurosciences, Cardiac Sciences, Orthopaedics & Traumatology
  • Initiated plans for Oncological (Cancer care) services during the year
  • Planning to open Hannah Joseph Hospital Pharmacy & Lab Services at K.K.Nagar, Madurai in FY 2026-27
  • SME IPO proceeds to support building and equipment for Oncology department (minimum 15 months development time)
  • No change in nature of business during the year

Corporate Actions

  • No transfer to reserves proposed
  • No subsidiaries, joint ventures, or associate companies
  • No material changes or commitments affecting financial position between year-end and report date

Related Party Transactions

Transactions with related parties conducted at arm's length basis, including:

  • Professional fees paid to Dr. Moses Joseph Arunkumar: ₹72.17 lakhs
  • Lease rent paid to Dr. Moses Joseph Arunkumar: ₹161.13 lakhs (including GST)
  • Unsecured loan taken from Dr. Moses Joseph Arunkumar: ₹278.25 lakhs
  • Interest paid on unsecured loan: ₹10.90 lakhs
  • Managerial remuneration to Dr. Moses Joseph Arunkumar: ₹505.25 lakhs
  • Managerial remuneration to Dr. Fenn Kavitha Fenn Arunkumar: ₹17.50 lakhs

CSR Activities

  • CSR obligation: ₹11.14 lakhs (2% of average net profit)
  • Amount spent on CSR: ₹4.63 lakhs
  • Unspent CSR amount: ₹6.50 lakhs transferred to unspent CSR account

Employee Information

  • Total permanent employees: 292
  • Gender composition: Male - 133, Female - 159, Transgender - 0
  • No complaints under Sexual Harassment of Women at Workplace Act, 2013
  • Complied with Maternity Benefit Act, 1961

Other Significant Information

  • No material orders passed by regulators/courts impacting going concern status
  • No frauds reported by statutory auditors
  • No application or proceedings under Insolvency and Bankruptcy Code, 2016
  • Adequate internal financial controls system in place
  • No deposits accepted during the year

Important Dates

  • Record Date for Dividend: July 08, 2026
  • Remote e-voting period: July 12, 2026 (09:00 AM) to July 14, 2026 (05:00 PM)
  • AGM Date: July 15, 2026 at 12:00 Noon